Relevant bibliographies by topics / Retinoblastoma, epigenetics, drug delivery system

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Retinoblastoma, epigenetics, drug delivery system'

Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Retinoblastoma, epigenetics, drug delivery system.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Retinoblastoma, epigenetics, drug delivery system"

1

Chen, Fengqian, Yunzhen Shi, Jinming Zhang, and Qi Liu. "Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy." Current Drug Targets 21, no. 11 (September 18, 2020): 1084–98. http://dx.doi.org/10.2174/1389450121666200514222900.

Full text
Abstract:
This review summarizes the epigenetic mechanisms of deoxyribonucleic acid (DNA) methylation, histone modifications in cancer and the epigenetic modifications in cancer therapy. Due to their undesired side effects, the use of epigenetic drugs as chemo-drugs in cancer therapies is limited. The drug delivery system opens a door for minimizing these side effects and achieving greater therapeutic benefits. The limitations of current epigenetic therapies in clinical cancer treatment and the advantages of using drug delivery systems for epigenetic agents are also discussed. Combining drug delivery systems with epigenetic therapy is a promising approach to reaching a high therapeutic index and minimizing the side effects.
APA, Harvard, Vancouver, ISO, and other styles
2

Gao, Ruijuan, Rajendra Narayan Mitra, Min Zheng, Kai Wang, Jesse Christine Dahringer, and Zongchao Han. "Developing Nanoceria-Based pH-Dependent Cancer-Directed Drug Delivery System for Retinoblastoma." Advanced Functional Materials 28, no. 52 (November 12, 2018): 1806248. http://dx.doi.org/10.1002/adfm.201806248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Su, Fanfan, Guogang Luan, Ming Guo, and Jinhua Wang. "Impact of resveratrol-containing peptide nanospheres on retinoblastoma cells." Materials Express 12, no. 12 (December 1, 2022): 1436–43. http://dx.doi.org/10.1166/mex.2022.2307.

Full text
Abstract:
For exploring an effective treatment of retinoblastoma (Rb), which is a threat to children, we constructed Resveratrol-peptide nanospheres (RES-PN) drug delivery system. Y-79 and S0-Rb50 cells were cultured to test the antitumor ability of RES-PN nanocomposites. In physicochemical properties test, we found PN could prolong RES half-life by about 3 times, and the particle size of RES-PN was about 214.10±3.73 nm, which was higher than that of PN (201.85±3.41 nm). Meanwhile, the encapsulation efficiency and drug loading rate of RES-PN were 90.77±3.51% and 9.82±0.64%, respectively. In the cell test, we found that RES-PN could better kill Rb cells and reduce their viability and invasiveness. Meanwhile, RES may induce Rb cell apoptosis through a mechanism possibly related to the JAK2/STAT3 axis. Hence, RES-PN shows great potential in Rb therapy.
APA, Harvard, Vancouver, ISO, and other styles
4

Yang, Fan, Zhihua Guo, Liuqi Shi, Zhanrong Li, Junjie Zhang, Chang Chai, and Jingguo Li. "Antiangiogenic and Antitumor Therapy for Retinoblastoma with Hypoxia-Inducible Factor-1α siRNA and Celastrol Co-Delivery Nanomicelles." Journal of Biomedical Nanotechnology 16, no. 10 (October 1, 2020): 1471–81. http://dx.doi.org/10.1166/jbn.2020.2983.

Full text
Abstract:
Retinoblastoma (RB) makes up about 3% of all childhood malignancies. Chemotherapy is commonly applied for RB treatment, while the clinical effectiveness varies significantly due to the cancer therapeutic resistances. Hypoxic tumor microenvironment, a hallmark of all tumors, is strongly associated with malignant progress and therapeutic resistances. The hypoxia mainly promotes the angiogenesis by upregulating pro-angiogenetic pathways. In this work, polymeric micelles are used as the carrier to deliver celastrol and siRNA to RB cells for achieving synergistic anti-tumor and antiangiogenesis effects. The micelle vectors have shown effective cellular internalization and release of loaded-celastrol and HIF-1 siRNA. The co-delivery system specifically and synergistically inhibits the expression of HIF-1α and VEGF in RB cells, suppresses the HIF-1α /VEGF/VEGFR signaling pathway, and impedes the proliferation, migration, and invasion of vascular endothelial cells. The polymer micellar carrier that co-delivers HIF-1α siRNA and celastrol is used for antiangiogenic and antitumor therapy of RB. Altogether, the results show that our polymeric micelle delivery system can be used to overcome barriers of drug resistance induced by angiogenesis and develop new drug/siRNA combinatory therapies.
APA, Harvard, Vancouver, ISO, and other styles
5

Yang, Fan, Zhihua Guo, Liuqi Shi, Zhanrong Li, Junjie Zhang, Chang Chai, and Jingguo Li. "Antiangiogenic and Antitumor Therapy for Retinoblastoma with Hypoxia-Inducible Factor-1α siRNA and Celastrol Co-Delivery Nanomicelles." Journal of Biomedical Nanotechnology 16, no. 10 (October 1, 2020): 1471–81. http://dx.doi.org/10.1166/jbn.2020.2983.

Full text
Abstract:
Retinoblastoma (RB) makes up about 3% of all childhood malignancies. Chemotherapy is commonly applied for RB treatment, while the clinical effectiveness varies significantly due to the cancer therapeutic resistances. Hypoxic tumor microenvironment, a hallmark of all tumors, is strongly associated with malignant progress and therapeutic resistances. The hypoxia mainly promotes the angiogenesis by upregulating pro-angiogenetic pathways. In this work, polymeric micelles are used as the carrier to deliver celastrol and siRNA to RB cells for achieving synergistic anti-tumor and antiangiogenesis effects. The micelle vectors have shown effective cellular internalization and release of loaded-celastrol and HIF-1 siRNA. The co-delivery system specifically and synergistically inhibits the expression of HIF-1α and VEGF in RB cells, suppresses the HIF-1α /VEGF/VEGFR signaling pathway, and impedes the proliferation, migration, and invasion of vascular endothelial cells. The polymer micellar carrier that co-delivers HIF-1α siRNA and celastrol is used for antiangiogenic and antitumor therapy of RB. Altogether, the results show that our polymeric micelle delivery system can be used to overcome barriers of drug resistance induced by angiogenesis and develop new drug/siRNA combinatory therapies.
APA, Harvard, Vancouver, ISO, and other styles
6

Sánchez-Molina, Sara, Elisabet Figuerola-Bou, Víctor Sánchez-Margalet, Luis de la Cruz-Merino, Jaume Mora, Enrique de Álava Casado, Daniel José García-Domínguez, and Lourdes Hontecillas-Prieto. "Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies." Cancers 14, no. 21 (November 7, 2022): 5473. http://dx.doi.org/10.3390/cancers14215473.

Full text
Abstract:
Ewing Sarcoma (EWS) is an aggressive bone and soft tissue tumor that mainly affects children, adolescents, and young adults. The standard therapy, including chemotherapy, surgery, and radiotherapy, has substantially improved the survival of EWS patients with localized disease. Unfortunately, this multimodal treatment remains elusive in clinics for those patients with recurrent or metastatic disease who have an unfavorable prognosis. Consistently, there is an urgent need to find new strategies for patients that fail to respond to standard therapies. In this regard, in the last decade, treatments targeting epigenetic dependencies in tumor cells and the immune system have emerged into the clinical scenario. Additionally, recent advances in nanomedicine provide novel delivery drug systems, which may address challenges such as side effects and toxicity. Therefore, therapeutic strategies stemming from epigenetics, immunology, and nanomedicine yield promising alternatives for treating these patients. In this review, we highlight the most relevant EWS preclinical and clinical studies in epigenetics, immunotherapy, and nanotherapy conducted in the last five years.
APA, Harvard, Vancouver, ISO, and other styles
7

Serpe, Loredana, Marilena Guido, Roberto Canaparo, Elisabetta Muntoni, Roberta Cavalli, Patrizia Panzanelli, Carlo Della Pepa, et al. "Intracellular Accumulation and Cytotoxicity of Doxorubicin with Different Pharmaceutical Formulations in Human Cancer Cell Lines." Journal of Nanoscience and Nanotechnology 6, no. 9 (September 1, 2006): 3062–69. http://dx.doi.org/10.1166/jnn.2006.423.

Full text
Abstract:
The structure of both carrier and anticancer drug affects the intracellular fate of a transported drug. The study investigated in vitro intracellular accumulation and cytotoxic activity of doxorubicin-loaded solid lipid nanoparticles (SLN), doxorubicin in pegylated liposomes (Caelyx<snm>®</snm>) and free doxorubicin. Intracellular doxorubicin levels and cytotoxic activity were determined by high performance liquid chromatography with fluorescence detection, and by the trypan blue dye exclusion assay, respectively. Doxorubicin-loaded SLN inhibited cell growth more strongly than either free or liposomal doxorubicin, in human colorectal adenocarcinoma, HT-29, retinoblastoma Y79, and glioblastoma U373 cell lines. The IC50 values for doxorubicin-loaded SLN were significantly lower after 24 h exposure than those for free doxorubicin in all cell lines; after 48 h exposure they were lower than those for liposomal doxorubicin in HT-29 and Y79 cells. The enhanced cytotoxic activity of doxorubicin-loaded SLN was associated with increased drug incorporation in cells: intracellular doxorubicin levels were significantly enhanced after exposure to drug-loaded SLN versus either free or liposomal drug. Rate of intracellular accumulation and cytotoxic activity also differed among different cell lines; in particular, cells of epithelial origin were found to be more sensitive to doxorubicin-loaded SLN. In conclusion, the greater sensitivity of HT-29, Y79, and U373 cells to doxorubicin-loaded SLN than to the other drug formulations may be due to the capability of the delivery system to enhance drug action, through a marked uptake and accumulation of SLN within the cell.
APA, Harvard, Vancouver, ISO, and other styles
8

Hashizume, Rintaro. "LW-10 PRECLINICAL THERAPEUTIC TESTING FOR BRAIN TUMOR USING PATIENT-DERIVED XENOGRAFT (PDX) MODEL." Neuro-Oncology Advances 4, Supplement_3 (December 1, 2022): iii27. http://dx.doi.org/10.1093/noajnl/vdac167.109.

Full text
Abstract:
Abstract I have been working on the brain tumor research about 20 years in the United State. My primary research interests in understanding of the mechanisms of genetic and epigenetic regulation that promote tumor development and progression, and identify novel therapeutic targets for the treatment of human brain cancer. For these purposes, I have developed many unique patient-derived xenograft (PDX) models for human brain tumors in the brains of immunocompromised mice. This animal model system has been shown to better preserve tumor characteristics, as manifested in patients, than tumor cell propagation in cell culture. In association with the development of these models, my laboratory utilizes numerous techniques to investigate brain tumor growth and response to novel agents that are administered singularly or in combinations, including with radiation. My laboratory employs the latest genomic/epigenomic technologies to identify novel genetic and epigenetics alteration that would reveal rational therapeutic targets, and test the anti-tumor activity of the therapeutics using PDX mouse model including diffuse intrinsic pontine glioma (DIPG) harboring histone H3 gene mutation (H3K27M). We have investigated the role of H3K27M mutations and histone modifications, and preclinical therapeutic testing in DIPG PDX models. In addition to the molecular targeted therapy, we recently implement AI machine learning approach and emerging patient genomic data to discover more effective and less toxic candidates from billions of compounds for brain tumor therapy. Moreover, we investigate new drug delivery systems to bypass the blood-brain barrier using convection-enhanced delivery and intranasal delivery. My long-term goal of my work further tests the efficacy of my approach preclinically and, if validated, move this therapeutic approach to clinical trial. In the meeting, I will present current advances in experimental therapeutics in my laboratory.
APA, Harvard, Vancouver, ISO, and other styles
9

Lu, Yanqin, Yiming Yang, Xiaohui Liu, Ning Li, Fen Hu, Bolin Zhang, Hao Dai, Haifeng Cai, and Yan Jinyin Yan. "Poly-2-oxazoline nanoparticles potentiate effectiveness of vismodegib for breast cancer through improvement in pharmacokinetics and reduction in systemic toxicity." Materials Express 12, no. 8 (August 1, 2022): 1020–26. http://dx.doi.org/10.1166/mex.2022.2242.

Full text
Abstract:
Breast cancer is one of the most significant health challenges in the world. Vismodegib has been used for treatment of breast cancer limits the prescriptions of this drug. Therefore, it is of great significance to improve therapeutic effect of vismodegib therapy. This study modified the vismodegib with poly-2-oxazoline (POx) nanoparticles (POx-vismo) and examined the therapeutic potential of this approach for treating breast cancer. After preparation of POx-vismo micelles, they were characterized and loading efficiency, which was also measured by high performance liquid chromatography. The POx-vismo and vismodegib were administered to mice with breast cancer and healthy, respectively. Tumor, forebrain and blood samples were taken for analysis of pharmacokinetics and measurement of toxicity, where the concentration of POx was determined. Pharmacodynamic response was evaluated and Western blot analysis was used to determine the expression of retinoblastoma protein (pRB) and proliferating cell nuclear antigen (PCNA). Compared with traditional vismodegib, POx-vismo significantly improved the delivery efficiency of drugs in central nervous system accompanied with higher level of vismodegib. Administration with POx-vismo greatly improved the pharmacokinetics, diminished the toxicity, and strengthened the efficacy. POx-vismo therapy more effectively suppressed tumor cell growth and decreased pRB expression than oral administration of vismodegib. Collectively, the POx effectively served as a carrier of vismodegib in breast cancer and brain. POx-vismo micelles suppressed breast cell growth with low toxicity and addition of POx can enhance the efficacy of vismodegib for breast cancer and improves pharmacokinetics and pharmacodynamic response. These findings provide a novel insight into the drug therapy against the disorder.
APA, Harvard, Vancouver, ISO, and other styles
10

Mott, Bryan T., Ankitha Iyer, Eleanor Smith, Kyle Fargen, Patrick Brown, and Stacey Quintero Wolfe. "Current Indications for Intraarterial Chemotherapy in Neurointerventional Surgery." Stroke: Vascular and Interventional Neurology, December 6, 2022. http://dx.doi.org/10.1161/svin.122.000425.

Full text
Abstract:
BACKGROUND In pursuit of a cure for cancer, it is imperative to utilize every tool, resource, and strategy. Included under this umbrella is the optimization of drug delivery. Broadly speaking, anti‐cancer treatment has been perpetually hindered by off‐target activity, systemic toxicity, and other adverse reactions. Intraarterial (IA) delivery of therapeutics is an approach that has garnered increased attention in recent years. This approach can deliver drug directly to the desired site with the potential to minimize systemic toxicity. METHODS In this review, we briefly cover existing IA indications for peripheral solid tumors as a base from which we can learn, followed by trials and procedural considerations of IA drug delivery for neck, head, and central nervous system tumors. RESULTS While the bulk of IA research and clinical trials have focused on drug delivery outside of the central nervous system, there have been recent encouraging results in IA tumor treatment within the neurointerventional arena, such as head and neck tumors, retinoblastoma, glioblastoma multiforme, and central nervous system lymphoma. CONCLUSION This review highlights the need for increased clinical research on IA chemotherapeutic delivery as a multi‐disciplinary approach involving neurointerventional surgeons.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Retinoblastoma, epigenetics, drug delivery system"

1

Naldi, Ilaria. "An innovative epigenetic strategy for retinoblastoma treatment." Doctoral thesis, 2017. http://hdl.handle.net/2158/1077144.

Full text
Abstract:
Retinoblastoma (Rb) is a rare cancer that nonetheless represents the most common ocular malignancy in children. The management of retinoblastoma often requires intensive chemotherapy and sometimes even surgery to preserve useful vision and quality of patient's life. Between the two retinoblastoma forms (familiar and sporadic), the incidence of the sporadic one is increasing and its pathogenesis is mostly unknown. Recently, the discovery of the epi/genetic nature of nonhereditable/ sporadic Rb led to the development of high-throughput precision investigation strategies for the study of its epigenetic landscape. Epigenetic alteration in gene silencing in Rb can become target for the reprogramming of cancer cells leading to apoptosis. There is therefore the need to expand the field of investigation to identify new more effective molecules and/or reliable minimally invasive treatments using drug delivery systems for more targeted therapy. This thesis evaluated the effect of the demethylating agent 5-Aza-2'-deoxycytidine (DAC) and of a new DAC-formulation based on erythrocyte drug delivery system (EMHVs DDS) for the treatment of Rb. The results showed that DAC induced an anti-proliferative effect in Rb cells by activating genes involved on apoptotic response. Using cDNA microarray analysis, a gene-gene network interaction study in cells treated with DAC identified numerous differential expressed genes (DEG). Among those, fifteen genes involved in initiation and progression of Rb, were chosen as candidates for targeted therapy. qRT-PCR validation confirmed the time-dependent variation of genes expression. Methylation analysis indicated the direct effect of DAC on both CASP8 and BIK while showing an indirect regulation on the other genes, such as FAS. Preclinical investigation of DAC therapy and epigenetic combinatory treatments (DAC and Trichostatin A) was carried out in xenograft and orthotopic models, indicating that DAC alone induced the most significant anti-cancer effect. EMHVs DDS was used to improve efficacy of DAC therapy as well as to deliver a new biodrug, Survivin Molecular Beacon (SURV-MB) with theranostic activity, targeting mRNA of BIRC5 oncogene overexpressed in Rb. The beneficial effect of using EMHVs DDS was lowering the dose of DAC and improving the bioavailability of both the active molecules. These results will open new perspective for localized, safe and target specific therapies in Rb. This work is seminal for further investigation on the possibility of using both the carrier and the formulations for the development of new therapeutic intervention in precision medicine.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography